Regeneron Pharmaceuticals (NASDAQ:REGN) Given New $584.00 Price Target at UBS Group

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) had its price target boosted by analysts at UBS Group from $560.00 to $584.00 in a report issued on Friday,Benzinga reports. The brokerage presently has a "neutral" rating on the biopharmaceutical company's stock. UBS Group's price target points to a potential upside of 3.25% from the company's previous close.

Several other brokerages have also commented on REGN. Royal Bank Of Canada lowered Regeneron Pharmaceuticals from a "moderate buy" rating to a "hold" rating and set a $662.00 price objective on the stock. in a report on Friday, May 30th. Wall Street Zen lowered Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Thursday, May 1st. Wells Fargo & Company lowered Regeneron Pharmaceuticals from an "overweight" rating to an "equal weight" rating and lowered their price target for the stock from $700.00 to $580.00 in a research note on Friday, May 30th. Bank of America lowered their price target on Regeneron Pharmaceuticals from $575.00 to $547.00 and set an "underperform" rating on the stock in a research note on Thursday, April 17th. Finally, Truist Financial lowered their price target on Regeneron Pharmaceuticals from $975.00 to $940.00 and set a "buy" rating on the stock in a research note on Wednesday, April 30th. One investment analyst has rated the stock with a sell rating, seven have given a hold rating, sixteen have issued a buy rating and three have assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $823.54.

Regeneron Pharmaceuticals Stock Performance

REGN stock traded up $5.86 during trading on Friday, hitting $565.62. 465,053 shares of the company traded hands, compared to its average volume of 912,369. The stock's 50-day simple moving average is $545.98 and its 200 day simple moving average is $621.52. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.93 and a quick ratio of 4.03. The company has a market cap of $61.07 billion, a PE ratio of 14.38, a P/E/G ratio of 2.06 and a beta of 0.33. Regeneron Pharmaceuticals has a 1 year low of $476.49 and a 1 year high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $8.22 EPS for the quarter, missing the consensus estimate of $8.83 by ($0.61). Regeneron Pharmaceuticals had a net margin of 31.94% and a return on equity of 15.27%. The business had revenue of $3.03 billion during the quarter, compared to analyst estimates of $3.40 billion. During the same period in the previous year, the business posted $9.55 earnings per share. The firm's revenue for the quarter was down 3.7% on a year-over-year basis. On average, equities analysts expect that Regeneron Pharmaceuticals will post 35.92 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Regeneron Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the business. Pinney & Scofield Inc. acquired a new stake in shares of Regeneron Pharmaceuticals in the 4th quarter valued at $25,000. Rakuten Securities Inc. raised its holdings in shares of Regeneron Pharmaceuticals by 62.5% in the 4th quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company's stock valued at $28,000 after purchasing an additional 15 shares in the last quarter. E Fund Management Hong Kong Co. Ltd. raised its holdings in shares of Regeneron Pharmaceuticals by 344.4% in the 1st quarter. E Fund Management Hong Kong Co. Ltd. now owns 40 shares of the biopharmaceutical company's stock valued at $25,000 after purchasing an additional 31 shares in the last quarter. Activest Wealth Management raised its holdings in shares of Regeneron Pharmaceuticals by 110.5% in the 1st quarter. Activest Wealth Management now owns 40 shares of the biopharmaceutical company's stock valued at $25,000 after purchasing an additional 21 shares in the last quarter. Finally, Costello Asset Management INC purchased a new position in shares of Regeneron Pharmaceuticals in the 1st quarter valued at $27,000. 83.31% of the stock is currently owned by institutional investors and hedge funds.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.